Tumour immunology - Tumour-induced immune modulation of sentinel lymph nodes

被引:203
作者
Cochran, Alistair J. [1 ]
Huang, Rong-Rong
Lee, Jonathan
Itakura, Eijun
Leong, Stanley P. L.
Essner, Richard
机构
[1] Univ Calif Los Angeles, Dept Pathol & Lab Med, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Surg Oncol, Inst Canc, New Brunswick, NJ 08901 USA
[3] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
[4] John Wayne Canc Inst, Dept Surg Oncol, Santa Monica, CA 90404 USA
[5] John Wayne Canc Inst, Dept Mol Therapeut, Santa Monica, CA 90404 USA
关键词
D O I
10.1038/nri1919
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Sentinel lymph nodes (SLNs), being the first nodes to receive lymph from a primary tumour and the preferential site of initial tumour metastases, are intensively exposed to the bioactive products of tumour cells and other associated cells. This makes them ideal for studies of the factors that determine selective tissue susceptibility to metastases. We postulate that tumour-induced immune modulation of SLNs facilitates lymph-node metastases by inhibiting the generation of tumour-specific cytotoxic T cells that are active against tumour cells of primary and metastatic melanomas. Immune modulation of the lymph nodes can be reversed by granulocyte/macrophage colony-stimulating factor (GM-CSF), a finding that has implications for the future therapy of lymph-node metastases.
引用
收藏
页码:659 / 670
页数:12
相关论文
共 122 条
[1]   IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients [J].
Ahmadzadeh, M ;
Rosenberg, ST .
BLOOD, 2006, 107 (06) :2409-2414
[2]   CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2 [J].
Antony, PA ;
Restifo, NP .
JOURNAL OF IMMUNOTHERAPY, 2005, 28 (02) :120-128
[3]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[4]   Cytokine expression and dendritic cell density in melanoma sentinel nodes [J].
Botella-Estrada, R ;
Dasí, F ;
Ramos, D ;
Nagore, E ;
Herrero, MJ ;
Giménez, J ;
Fuster, C ;
Sanmartín, O ;
Guillén, C ;
Aliño, S .
MELANOMA RESEARCH, 2005, 15 (02) :99-106
[5]   Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs [J].
Calzascia, T ;
Masson, F ;
Di Berardino-Besson, W ;
Contassot, E ;
Wilmotte, R ;
Aurrand-Lions, M ;
Rüegg, C ;
Dietrich, PY ;
Walker, PR .
IMMUNITY, 2005, 22 (02) :175-184
[6]   Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma [J].
Cesana, GC ;
DeRaffele, G ;
Cohen, S ;
Moroziewicz, D ;
Mitcham, J ;
Stoutenburg, J ;
Cheung, K ;
Hesdorffer, C ;
Kim-Schulze, S ;
Kaufman, HL .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1169-1177
[7]   Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence [J].
Clary, BM ;
Brady, MS ;
Lewis, JJ ;
Coit, DG .
ANNALS OF SURGERY, 2001, 233 (02) :250-258
[8]  
COCHRAN AJ, 1989, ANTICANCER RES, V9, P859
[9]   Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumours [J].
Cochran, AJ ;
Roberts, A ;
Wen, DR ;
Huang, RR ;
Itakura, E ;
Luo, F ;
Binder, SW .
PATHOLOGY, 2004, 36 (05) :478-484
[10]  
Cochran AJ, 2000, CANCER, V89, P236, DOI 10.1002/1097-0142(20000715)89:2<236::AID-CNCR5>3.0.CO